Phenotype of EBV-infected PBMCs from subjects
| Patient . | Diagnosis . | EBV DNA load/106 cells . | Percent of EBV-positive cells (no. positive/total no. cells) . | ||||
|---|---|---|---|---|---|---|---|
| B cells . | Plasmablast/plasma cells . | Non-B, non-T, nonmonocyte cells . | T cells . | Monocytes . | |||
| 1 | HIV | 12 000 | 75 (3/4) | ND | 25 (1/4) | 0 | 0 |
| 2 | HIV | 4300 | 89 (8/9) | 0 | 11 (1/9) | 0 | 0 |
| 3 | HIV | 18 000 | 91 (10/11) | 0 | 9 (1/11) | 0 | 0 |
| 4 | HIV | 130,000 | 71 (12/17) | 67 (6/9) | 29 (5/17) | 0 | 0 |
| 5 | HIV | 9400 | 25 (1/4) | 0 | 25 (1/4) | 25 (1/4) | 25 (1/4) |
| 6 | HIV | 5100 | 100 (11/11) | 0 | 0 | 0 | 0 |
| 7 | HIV | 22 000 | 67 (10/15) | 50 (4/8) | 20 (3/15) | 0 | 13 (2/15) |
| 8 | HIV | 6300 | 82 (9/11) | 17 (1/6) | 18 (2/11) | 0 | 0 |
| 9 | Tx | NA | 100 (4/4) | 0 | 0 | 0 | 0 |
| 10 | Tx | 30 000 | 92 (12/13) | 0 | 8 (1/13) | 0 | 0 |
| 11 | Tx | 6200 | 83 (5/6) | ND | 17 (1/6) | 0 | 0 |
| 12 | LyG/HL | 170 000 | 64 (49/77) | 0 | 6 (5/77) | 27 (21/77) | 3 (2/77) |
| 13 | Severe primary EBV infection | 280 000 | 90 (30/33) | 0 | 10 (3/33) | 0 | 0 |
| 14 | PTLD | 1 300 000 | 55 (11/20) | 25 (2/8) | 45 (9/20) | 0 | 0 |
| 15 | ATL EBV-LPD | 190 000 | 79 (19/24) | 21 (3/14) | 21 (5/24) | 0 | 0 |
| 16 | LyG | 28 000 | 79 (15/19) | 14 (1/7) | 21 (4/19) | 0 | 0 |
| 17 | ICL | 110 000 | 97 (28/29) | 0 | 3 (1/29) | 0 | 0 |
| 18 | AA | 64 000 | 80 (8/10) | ND | 20 (2/10) | 0 | 0 |
| 19 | AA | 110 000 | 89 (17/19) | 20 (1/5) | 0 | 0 | 5 (1/19) |
| 20 | AA | 6 500 000 | 52 (24/46) | 37 (6/16) | 48 (22/46) | 0 | 0 |
| 21 | B-cell CAEBV | 15 000 | 73 (11/15) | 20 (1/5) | 27 (4/15) | 0 | 0 |
| 22 | B-cell CAEBV | 30 900 | 97 (29/30) | 0 | 3 (1/30) | 0 | 0 |
| 23 | B-cell CAEBV | 310 000 | 80 (12/15) | 25 (2/8) | 20 (3/15) | 0 | 0 |
| 24 | T-cell CAEBV | 54 666/μg | 0 | ND | 0 | 100 (88/88) | 0 |
| 25 | T-cell CAEBV | 67 612/μg | 0 | ND | 0 | 100 (21/21) | 0 |
| 26 | T-cell CAEBV | 230 000/μg | 0 | ND | 0 | 100 (78/78) | 0 |
| 27 | T-cell CAEBV | 4154/μg | 0 | ND | 0 | 100 (18/18) | 0 |
| 28 | IM | 1700 | 83 (10/12) | 17 (1/6) | 0 | 0 | 0 |
| 29 | IM | 10 651 | 100 (11/11) | 0 | 0 | 0 | 0 |
| Patient . | Diagnosis . | EBV DNA load/106 cells . | Percent of EBV-positive cells (no. positive/total no. cells) . | ||||
|---|---|---|---|---|---|---|---|
| B cells . | Plasmablast/plasma cells . | Non-B, non-T, nonmonocyte cells . | T cells . | Monocytes . | |||
| 1 | HIV | 12 000 | 75 (3/4) | ND | 25 (1/4) | 0 | 0 |
| 2 | HIV | 4300 | 89 (8/9) | 0 | 11 (1/9) | 0 | 0 |
| 3 | HIV | 18 000 | 91 (10/11) | 0 | 9 (1/11) | 0 | 0 |
| 4 | HIV | 130,000 | 71 (12/17) | 67 (6/9) | 29 (5/17) | 0 | 0 |
| 5 | HIV | 9400 | 25 (1/4) | 0 | 25 (1/4) | 25 (1/4) | 25 (1/4) |
| 6 | HIV | 5100 | 100 (11/11) | 0 | 0 | 0 | 0 |
| 7 | HIV | 22 000 | 67 (10/15) | 50 (4/8) | 20 (3/15) | 0 | 13 (2/15) |
| 8 | HIV | 6300 | 82 (9/11) | 17 (1/6) | 18 (2/11) | 0 | 0 |
| 9 | Tx | NA | 100 (4/4) | 0 | 0 | 0 | 0 |
| 10 | Tx | 30 000 | 92 (12/13) | 0 | 8 (1/13) | 0 | 0 |
| 11 | Tx | 6200 | 83 (5/6) | ND | 17 (1/6) | 0 | 0 |
| 12 | LyG/HL | 170 000 | 64 (49/77) | 0 | 6 (5/77) | 27 (21/77) | 3 (2/77) |
| 13 | Severe primary EBV infection | 280 000 | 90 (30/33) | 0 | 10 (3/33) | 0 | 0 |
| 14 | PTLD | 1 300 000 | 55 (11/20) | 25 (2/8) | 45 (9/20) | 0 | 0 |
| 15 | ATL EBV-LPD | 190 000 | 79 (19/24) | 21 (3/14) | 21 (5/24) | 0 | 0 |
| 16 | LyG | 28 000 | 79 (15/19) | 14 (1/7) | 21 (4/19) | 0 | 0 |
| 17 | ICL | 110 000 | 97 (28/29) | 0 | 3 (1/29) | 0 | 0 |
| 18 | AA | 64 000 | 80 (8/10) | ND | 20 (2/10) | 0 | 0 |
| 19 | AA | 110 000 | 89 (17/19) | 20 (1/5) | 0 | 0 | 5 (1/19) |
| 20 | AA | 6 500 000 | 52 (24/46) | 37 (6/16) | 48 (22/46) | 0 | 0 |
| 21 | B-cell CAEBV | 15 000 | 73 (11/15) | 20 (1/5) | 27 (4/15) | 0 | 0 |
| 22 | B-cell CAEBV | 30 900 | 97 (29/30) | 0 | 3 (1/30) | 0 | 0 |
| 23 | B-cell CAEBV | 310 000 | 80 (12/15) | 25 (2/8) | 20 (3/15) | 0 | 0 |
| 24 | T-cell CAEBV | 54 666/μg | 0 | ND | 0 | 100 (88/88) | 0 |
| 25 | T-cell CAEBV | 67 612/μg | 0 | ND | 0 | 100 (21/21) | 0 |
| 26 | T-cell CAEBV | 230 000/μg | 0 | ND | 0 | 100 (78/78) | 0 |
| 27 | T-cell CAEBV | 4154/μg | 0 | ND | 0 | 100 (18/18) | 0 |
| 28 | IM | 1700 | 83 (10/12) | 17 (1/6) | 0 | 0 | 0 |
| 29 | IM | 10 651 | 100 (11/11) | 0 | 0 | 0 | 0 |
For some patients, the percentages for each subpopulation total to > 100%, because the same cell marker (eg, CD20 for B cells) was used in more than one combination (eg, CD20 with CD3 and CD14 in one combination, CD20 with kappa/lambda in another combination). Patients with HIV infection had CD4 T-cell counts < 400/μL and no EBV-positive lymphomas. Patient 21 received rituximab therapy 1 month before blood was drawn; patients 10, 11, 18, 19, and 20 received anti-thymocyte globulin 5 days to 1 month before blood was drawn (patient 18 received rabbit anti-thymocyte globulin, and patients 10, 11, 18, 19, and 20 received horse anti-thymocyte globulin).
ND indicates not done; Tx, allogeneic hematopoietic stem cell transplant recipient; LyG/HL, lymphomatoid granulomatosis/Hodgkin lymphoma; ATL EBV-LPD, adult T-cell leukemia and EBV-lymphoproliferative disease; ICL, idiopathic CD4 lymphopenia; AA, aplastic anemia receiving antithymocyte globulin; and IM, EBV infectious mononucleosis.